Bristol-myers Squibb Compnay

Viiv Healthcare UK (no.5) Limited

Controlled Chemicals, Inc.

Zhiwei Guo

Animesh Goswami

Ramesh N Patel

Ronald L Hanson

Nicholas A Meanwell

Jeffrey A Robl

Alicia Regueiro-Ren

David R Kronenthal

Jacob Swidorski

Yuping Qiu

Zheng Liu

Jules A Shafer

Xiang-Yang Ye

Steven L Goldberg

Zhongping Shi

Prashant P Deshpande

Adrian Ortiz

Vladislav V Telyatnikov

Kishta Katipally

Tamas Benkovics

Chris Sfouggatakis

Yijun Chen

Linda Nga Hoong Chu

Robert M Johnson

Thomas P Tully

Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, betulinic acid derivaties that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formulas I, II and III: These compounds are useful for the treatment of HIV and AIDS.

Betulinic acid derivatives with HIV maturation inhibitory activity

A process for making the compound of Formula I utilizes the starting compound, together with sulfilimine and sulfoxide process steps later on. 

Sulfilimine and sulphoxide methods for producing festinavir

The present disclosure provides a method for the stereospecific hydrolysis of racemic 1,1-dialkyloxycarbonylcyclopropanes.

Process for resolving cyclopropyl diesters

Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-Beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds have the structure: enantiomers, diastereomers, solvates, or salts thereof, wherein A, W, X and Z are defined herein.

Cyclic 11-beta hydroxysteroid dehydrogenase type 1 inhibitors

The invention relates to a process for the enzymatic, stereoselective reduction of ketone compounds to provide chiral alcohols, for example the compound of formula Ib: 

Stereoselective reduction process for the preparation of pyrrolotriazine compounds

The abuse potential of a bioavailable drug such as an opiate analgesic agent is reduced and its duration of action is extended by converting it to a poorly absorbed ester prodrug or other prodrug derivative prior to formulation. Unlike many existing sustained release formulations of active pharmaceutical agents wherein an active pharmaceutical agent can be released by chewing, crushing, or otherwise breaking tablets or capsule beads containing the active pharmaceutical agent, such mechanical processing of tablets or capsule beads containing a prodrug of this invention neither releases the active drug nor compromises the controlled conversion of prodrug to drug. Moreover, tablets and capsule beads containing prodrugs of this invention or other drugs can be formulated with a sufficient amount of a thickening agent such as hydroxypropylmethylcellulose or carboxymethylcellulose to impede inappropriate intravenous and nasal administration of formulations that are not indicated for these modes of administration.

Compounds and methods for lowering the abuse potential and extending the duration of action of a drug

Growing community of inventors

Franklin Park, NJ, United States of America

Zhiwei Guo